232 related articles for article (PubMed ID: 22129044)
1. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
Huijts CM; Santegoets SJ; van den Eertwegh AJ; Pijpers LS; Haanen JB; de Gruijl TD; Verheul HM; van der Vliet HJ
BMC Cancer; 2011 Nov; 11():505. PubMed ID: 22129044
[TBL] [Abstract][Full Text] [Related]
2. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Werter IM; Huijts CM; Lougheed SM; Hamberg P; Polee MB; Tascilar M; Los M; Haanen JBAG; Helgason HH; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 May; 68(5):787-798. PubMed ID: 30756132
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
Huijts CM; Werter IM; Lougheed SM; Goedegebuure RS; van Herpen CM; Hamberg P; Tascilar M; Haanen JB; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 Feb; 68(2):319-329. PubMed ID: 30413837
[TBL] [Abstract][Full Text] [Related]
4. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
5. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
Huijts CM; Lougheed SM; Bodalal Z; van Herpen CM; Hamberg P; Tascilar M; Haanen JB; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 Mar; 68(3):503-515. PubMed ID: 30652208
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
Harshman LC; Barbeau S; McMillian A; Srinivas S
Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
[TBL] [Abstract][Full Text] [Related]
9. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
10. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
12. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
13. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
[TBL] [Abstract][Full Text] [Related]
14. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Tsimafeyeu I; Snegovoy A; Varlamov S; Safina S; Varlamov I; Gurina L; Manzuk L
Target Oncol; 2015 Sep; 10(3):423-7. PubMed ID: 25466382
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]